You are here: Staff
PPA signature

  • Click here to read our new paper on the diagnosis and monitoring of primary progressive aphasia.
  • Other news  

Welcome to the MGH FTD Unit

Document Actions

The staff of the MGH Frontotemporal Disorders (FTD) Unit includes:

Dr. Brad Dickerson, M.D., Director (Behavioral neurologist)
Daisy Sapolsky, M.S., CCC-SLP, Founding Speech and Language Pathologist (currently on leave)
Dr. Scott McGinnis, M.D., Director of Clinical Trials (Behavioral neurologist)
Dr. Mark Eldaief, M.D. (Behavioral neurologist)
Dr. David Perez, M.D. (Behavioral neurologist)
Dr. Elena Ratti, M.D. (FTD-ALS neurologist)
Dr. Kimiko Domoto-Reilly, M.D., Behavioral Neurology fellow
Affiliated Faculty
Paige Nalipinski, M.S., CCC-SLP, Senior Speech and Language Pathologist
Dr. Janet Sherman, Ph.D., Director of Neuropsychology
Dr. Cathy Leveroni, Ph.D., Neuropsychologist
Dr. David Caplan, M.D., Ph.D., Behavioral Neurologist and Linguist
Dr. Belen Pascual, Ph.D., Research fellow
Former members

Dr. Kimiko Domoto-Reilly, M.D., Behavioral Neurology fellow
Dr. Simon Ducharme, M.D., Clinical research fellow
Dr. Belen Pascual, Ph.D., Research fellow
Dr. Kristen Lindquist, Ph.D., Research fellow
Alyson Negreira, B.S., Lab manager/research assistant
Akram Bakkour, B.S., Neuroimaging Technologist
Dr. Lucille Pellerin, M.D., Visiting clinical research fellow

The MGH FTD Unit aims to develop better knowledge about and diagnosis and treatment of all forms of FTD and related focal dementia syndromes. The PPA Program aims to better understand and treat primary progressive aphasia syndromes using existing technologies (including speech therapy) and by developing new diagnostic and treatment technologies.

Our research is generously funded by the National Institute on Aging and the Alzheimer's Association.

Created by admin
We are an interdisciplinary team of clinicians and researchers who are dedicated to the belief that, through the application of scientific approaches, we will advance our collective understanding of brain function and dysfunction which will ultimately improve our ability to diagnose, monitor, and treat patients with FTD and related disorders.